Solid Tumors Clinical Trials in Houston, Texas

21 studies are recruiting for solid tumors in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center ( Site 0007), Houston, Texas

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

2. A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

   This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Local Institution - 0085, Houston, Texas

   Locations

   58 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07492680 on ClinicalTrials.gov

3. A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

   A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Md Anderson Cancer Center, Houston, Texas

   Locations

   22 in total

   Run by

   Incyte Corporation

   See if you can join NCT07195916 on ClinicalTrials.gov

4. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

   The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Investigative Site US011, Houston, Texas

   Locations

   229 in total

   Run by

   Incyte Corporation

   See if you can join NCT07522073 on ClinicalTrials.gov

5. A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

   This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   14 in total

   Run by

   BeOne Medicines

   See if you can join NCT07181681 on ClinicalTrials.gov

6. A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

   The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.

   Stage

   Phase 2

   Ages

   0 to 17

   Site

   UT MD Anderson Cancer Center, Houston, Texas

   Locations

   5 in total

   Run by

   Spectrum Pharmaceuticals, Inc

   See if you can join NCT04570423 on ClinicalTrials.gov

7. A Study of ZL-1310 in Participants With Selected Solid Tumors

   A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Locations

   23 in total

   Run by

   Zai Lab (Shanghai) Co., Ltd.

   See if you can join NCT06885281 on ClinicalTrials.gov

8. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

   The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E…

   Stage

   Phase 2

   Ages

   8 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   70 in total

   Run by

   Fore Biotherapeutics

   See if you can join NCT05503797 on ClinicalTrials.gov

9. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

   To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   39 in total

   Run by

   Incyte Corporation

   See if you can join NCT05836324 on ClinicalTrials.gov

10. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Md Anderson Cancer Center, Houston, Texas

    Locations

    34 in total

    Run by

    Incyte Corporation

    See if you can join NCT06179160 on ClinicalTrials.gov

11. Study of AUBE00 in Patients With Solid Tumors

    This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total numb…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    4 in total

    Run by

    Chugai Pharmaceutical

    See if you can join NCT07030959 on ClinicalTrials.gov

12. Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors

    To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Md Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06651593 on ClinicalTrials.gov

13. JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

    This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research site, Houston, Texas

    Locations

    15 in total

    Run by

    Jacobio Pharmaceuticals Co., Ltd.

    See if you can join NCT06386146 on ClinicalTrials.gov

14. DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

    A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

    Stage

    Phase 2

    Ages

    18 and older

    Site

    USA12-0, Houston, Texas

    Locations

    37 in total

    Run by

    DualityBio Inc.

    See if you can join NCT06953089 on ClinicalTrials.gov

15. Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

    To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06066424 on ClinicalTrials.gov

16. QTX3034 in Patients With KRAS G12D Mutation

    Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson, Houston, Texas

    Locations

    14 in total

    Run by

    Quanta Therapeutics

    See if you can join NCT06227377 on ClinicalTrials.gov

17. A Study of HS-20110 in Participants With Advanced Solid Tumors

    This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    8 in total

    Run by

    Hansoh BioMedical R&D Company

    See if you can join NCT06892379 on ClinicalTrials.gov

18. S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

    The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab. The primary objective of Parts B and C is to evaluate the antitumor activity of …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    8 in total

    Run by

    Shionogi

    See if you can join NCT05101070 on ClinicalTrials.gov

19. A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

    The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #8, Houston, Texas

    Locations

    9 in total

    Run by

    Exelixis

    See if you can join NCT07123103 on ClinicalTrials.gov

20. Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

    The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    NEXT Houston, Houston, Texas

    Locations

    9 in total

    Run by

    Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

    See if you can join NCT06963281 on ClinicalTrials.gov

21. A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

    The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    8 in total

    Run by

    Adcentrx Therapeutics

    See if you can join NCT06710379 on ClinicalTrials.gov